· The results of an 8-week placebo-controlled intervention study in people with Subjective Cognitive Impairments (SCI) demonstrated improved cognitive load after the use of Brain+' Computerized Cognitive Training (CCT) games
· Some far-transfer effects of the CCT training were also seen in the participant's performance in a shopping task
· The indications of clinical feasibility of the CCT technology and the Starry Night cognitive test, provide early support for the Company's pipeline product for Mild Cognitive Impairment, which combines CCT, Starry Night, and Cognitive Stimulation Therapy (CST)
A study conducted by
People with SCI have an increased risk of developing dementia and are therefore a highly relevant segment for Brain+.
Study design
86 participants with SCI were recruited and followed through an 8-week intervention with Brain+ 1st generation CCT games. The participants were assigned to either the experimental group (trained with adaptive game versions) or the placebo control group (trained with non-adaptive game versions). The training took place 5 days a week, 20 minutes a day for 8 weeks.
All the participants underwent 1) standard cognitive assessments on attention and working memory, 2) brain imaging during a demanding working memory task, which was the Starry Night cognitive test developed by Brain+ and the
Two Brain+ technologies, CCT and the Starry Night cognitive test, were evaluated in the study
The study evaluated 1) the Brain+ CCT games, which provided the cognitive training element of the intervention, and 2) the Starry Night memory test, which was used to test working memory while participants underwent brain imaging.
The 1st Generation CCT games and the Starry Night cognitive test have been developed as part of an EU-Horizon2020 funded innovation project led by Brain+ and with partners
CCT and Starry Night are key components in a pipeline product for people with Mild Cognitive Impairment
The indications of clinical feasibility of the CCT technology are important as the 2nd Generation of CCT games will be a central component in a product Brain+ has in pre-clinical development for people with Mild Cognitive Impairment (MCI). MCI is a pre-stage to dementia and a clinical diagnosis, which is affecting an estimated 150-200 million people worldwide.
The MCI targeting product is the third in Brain+'s pipeline, envisioned to combine CCT and the Starry Night cognitive test as an integrated monitoring tool with the Cognitive Stimulation Therapy (CST) technology.
The CST technology is the most advanced of Brain+'s platforms as it is the foundation for the CST-Therapist Companion and the CST-Therapist Home Care products. A Danish version of CST-Therapist Companion was introduced commercially in Q4 2022, while German and
Contact Information
CEO,
About Computerized Cognitive Training (CCT)
Brain+ began the initial medical exploration of Computerized Cognitive Training (CCT) aiming at cognitive rehabilitation of brain injury patients, based on existing literature and approaches, which largely used training paradigms based on cognitive tests that were then adapted and gamified for training purposes. The 1st Generation CCT is based on this approach with certain adaptations. With a focused mission to address dementia and Alzheimer's disease and with recent insights on cognitive training, the 2nd generation cognitive training now targets very specific cognitive domains relevant to the disease area and the utilization of behavioral interventions that have already proven effective based on clinical studies in dementia and Mild Cognitive Impairment specifically. The 2nd generation Brain+ CCT is being developed and validated in the currently ongoing €1.5 million 'ACTTDCS' innovation project, funded by Eurostars and the
About Starry Night
The Starry Night functional prototype was completed in 2021, and the first study of this technology was done by the
The mission of Brain+ is to make effective treatments for cognitive decline in Alzheimer's accessible to everyone as digital therapeutics
https://news.cision.com/brain--a-s/r/results-from-a-clinical-study-provide-promising-feasibility-indications-for-brain--cct-technology-fo,c3696044
https://mb.cision.com/Public/20893/3696044/b076b0bf28773e13.pdf
https://news.cision.com/brain--a-s/i/1-b-en-rgb,c3132400
(c) 2023 Cision. All rights reserved., source